Overview
PT-141, also known as Bremelanotide, is a synthetic peptide derived from Melanotan II. Originally researched for its ability to induce skin tanning, scientists discovered it had a profound impact on sexual arousal. Unlike traditional medications for erectile dysfunction that focus on the vascular system and blood flow, PT-141 operates through the central nervous system by stimulating receptors in the brain. This unique neurological approach makes it effective for both men and women.
In clinical settings, PT-141 has gained significant recognition, earning FDA approval for treating low sexual desire in premenopausal women. Beyond its use for sexual dysfunction, it is often utilized to enhance libido and overall sexual satisfaction. Because it bypasses the cardiovascular mechanisms used by common ED drugs, it serves as a vital alternative for patients who may not tolerate or respond to standard treatments, effectively bridging the gap between physical and psychological sexual health.
Mechanism of action
PT-141 is a melanocortin receptor agonist that specifically targets MC3R and MC4R in the central nervous system. By stimulating the hypothalamus, it triggers a neurological response that enhances sexual arousal and desire.
Reported benefits
- ▸Significantly boosts libido and sexual desire in both males and females.
- ▸Assists in achieving and maintaining firm erections by acting on the nervous system.
- ▸Approved for treating Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women.
- ▸Functions through mental and neurological pathways rather than just increasing blood flow.
- ▸Provides a potential alternative for those who do not respond to PDE-5 inhibitors like Viagra.
Reported side effects
- ·Nausea
- ·Headache
- ·Flushing
- ·Blurred vision (rare)
- ·Dizziness
Often stacked with
Not specified